Eli Lilly Japan K.K. has decided to invest 20 billion yen in its Seishin Plant (Kobe City, Hyogo Prefecture), the only manufacturing base for its own products in Japan. In order to further strengthen Lilly's capacity to supply pharmaceuticals to the Japanese market, the company plans to introduce new production lines and construct a new warehouse building between 2026 and 2028, as well as optimise the Seishin Plant through the promotion of digitalisation and process automation.
At Eli Lilly Japan, it is crucial to respond quickly and flexibly to future supply expansions, driven by increasing demand for Lilly's innovative medicines and the expansion of its R&D pipeline, particularly in key areas such as diabetes, obesity, cancer, central nervous system disorders including Alzheimer's disease, and autoimmune diseases.
To date, the company has invested 7 billion yen at the Seishin Plant between 2022 and 2025, including the introduction of automated device sorting equipment, improvements to the quality testing laboratory, construction of a new plant building, and the introduction of a new packaging line. This additional investment was decided upon based on the belief that further strengthening of supply capacity is necessary.
To flexibly respond to the increasing demand for pharmaceuticals, the Seishin Plant has invested in state-of-the-art equipment, as well as working to improve the workplace environment and foster a corporate culture that allows diverse employees to work in a way that suits them. In order to deliver pharmaceuticals to the many patients who need them as quickly as possible, the Seishin Plant will continue to pursue a stable and high-quality pharmaceutical supply system.
